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Objeclivm The aim of this study wm to determine whether 
therapy with a beta.adrenergic orc&am ehanael btocLiag agent 
can improve the functimrd cap&y and qurlity of ttte of pattents 
with mitd or moderately symptomatic hylrrrtrophic mdtomyop. 
stby. 
B&ground. Both kta~blockers andc&urn cbnnnal bbxkers 
may alkvtate symp(omr in hypcrtrophlc cardtcmtyopathy, hut 
pmkws tlldks have been tiormed in bwdtatized rattents or
-&we been open studies wilhout control sabje&. _ 
Mefhods. A rsndanized, dwbIe.bttnd cro~ylvcc trtd of mad- 
in la pstieotr with or m&r&y 
symptomatic hypairophic cardiamyopatby (10 men, 8 wmen; 
mean age t SD 39 + 17 years,. A detntkd swptam ,wessment, 
Mcyete xerctse testing, echocaraioersphy and Ii&r monitwtne 
were porfmned in&h prtal. 
Rcsrrlrs. Two patients withdrew from tb study owing to 
symptomatic sinus bradycardia during nadolol therapy. Neither 
Beta-adrenergic receptor and calcium channel blocking 
agents are the mainstay of medical therapy in symptomatic 
hypertrophic cardiomyopathy (l,Z). The mechanisms by 
which these drugs have their beneficial effects in hypertro- 
phic cardiomyopathy have been extensively studied and 
reviewed (3-5). Studies of their symptomatic efficacy have 
largely been performed in hospitalized or highly symptom- 
die patients, often without a control group receiving placebo 
(6-S). Clinical reports (9,lO) and an unblinded, nonrandom- 
ized series of matched pairs of patients (1 I) have suggested 
that better symptomatic relief is obtained with vempamil 
ver&mJ 23 f 6, n&tot 21-k 7 nd!kg &r mi& p = 0.1). Peak 
exe& work toad was reduced by 210 Win 13 @ents (81%) 
duriog naddd therapy mxt io 4 patients (25%) d&g vempamit 
therapy @ = 0.003, rmddd vs. verapam@. Oppite the e6ec‘ccb M 
exercbe capadly, 13 patlent (81%) preferred drug tibnent (8 
vempamil, 5 aadalot) aw p!acebo (p = 0.001). Vera* 
baprwed repwted *ormaw at work compared with nadald 
(p = O.Ol)aod tended to bnpmveotbu meawmofheaUh.relrted 
behavior and symF&ms mmpmed with a&k4 and ataceba. 
Concluskm. In p-atknts rith mitd 01 maderate,y s-ymptomrtic 
hywttwhk cwdttmywatby, exe&e capacity WPP not im- 
proved by nadotot r verrpamit, and indivtdnab were more otten 
impaired by n&Id than with verapamil. Neverttwtem, many 
palimls derived symptcmattc benetil fmm drug therapy, ap 
eldty wttb vcrapmu. 
(I Ain Cdl Cudid 1993~1:16i’-9) 
than with propranolol. The only placebo-controlled cross- 
over trial of amwanolol and verapamil (12) was rmrformed in 
hospitalized’pa&ts and did notshow any sign&at differ- 
ence between the improvements in exercise capacity for 
each drug, bat mme patients felt batter during verapamil 
therapy. Therefore, the question remains whether such drug 
therapy can truly improve functional capacity and quality of 
life in mild and moderately symptomatic patients and, if so, 
which is the better agent. This question is impwmt because 
patients with hypertrophic cardiomyopathy frequently have 
only mild or moderate symptoms (13), and it may be uncer- 
tain whether this is due to truly mild limitation or is a result 
of life-style adjustment. To address this question, we under- 
took a double-blLd. olacebo-controlled trial of a calcium 
channel blocker (vera~tnil) and a beta-blocker (nadolol) in 
patients with mild to moderately symptomatic hypertmphic 
cardiomyopathy. 
Verapamil was chosen because it has the best protile of 
the calcium antagonists tested in hypertrophic cardiomyop- 
athy, namely, verapamil (14,15), nifedipine (16,17) and dtlt- 
iazem (18,19), and it is the only one in which long-ferm 
follow-up is available (6,7). Traditionally. propranolol, a 
Txbie 1. Clinical and Echocardiographic Chmctenstics of 18 Study Patients 
noucardioselective beta-blotter, has been used in hypertm- 
phic cardiomyopalty (20.21). Cardioselective agents may 
not be as effective owing to lack of peripheral beta- 
adrenergic receptor blockade and consrqurnt decreased 
peripheral vascular resistance (22). The noncardioseleclive 
beta-blocker nadolo! was chosen ova propmuolol because it 
lacks first-pass hepatic metabolism. thus giving more cousis- 
tent dose respouscs, a once daily administration and less 
frequent neurologic side effects (23.24). 
Methods 
Patients. The study was appmved by the Hospital Ethics 
Committee. All subjects gave written. informed consent. 
Hytwtrophic cardiomyopathy was diagnosed as previously 
d&cd &. Cons&i& o;tpatie&who we& in New 
York Hext Association functional class I or II. with or 
without medication, were invited to participate. Exclusion 
criteria were I) func!ionsl class Ill or IV; 2) chronic atrial 
fibrillation: 3) history of symptomatic bradycardia or heart 
rate a: rest <:I% beatsimin (without treatment); 4) systolic 
blood pressure <lo0 mm Hg (without treatment); 5) &&a- 
indication to the use of beta-blockers or calcium antaeouists. 
or bo!h. Eighteen patients were enrolled (IO male, S female 
with a mean we ? SD of 39 i I7 vears). Their ciinical 
characteristics are detailed in Table I.’ 
Concurrent therapy. Patients were enrolled whelher or 
not their current therapy was providing symptomatic benefit. 
Eight patients were not currently receiving drug thempy 
jseven had never received any drug therapy). Ten patients 
were receiving beta-blockers or ctdcntm antagonists, or 
both, for a variable period (3 mouths to 5 years) before the 
s!udy. and these agents were withdrawn gradually so that 
patients received no treatment for 3 seeks before the study. 
Patients receiving low dose amiodarone therapy were not 
excluded because amicdarone mw, reduce the risk of sudden 
death but not relieve symptotus (261, thus necessitating 
concurrent medication. 
Study design and drug admitdstrrdlun. The study wus a 
double-blind, three-period crossuver trial with a I-week 
washodt interval between each period. A double-dummy 
technique of drug administratien wus used. Two dosage 
regimens were prepared: regular = nadolol (Coward), SC mg 
once daily, or vempamil (Securon SR). 240 rug once daily; 
high = nadolol. 80 mg twice daily. or verdpamil. 240 mg 
twice dailv. A rwular dose was administered in the 1st week 
of each p&ad. The patients proceeded to a high dose for 3 
weeks if the followi& criteria were met: I) heart rate ut rest 
>K! beatsimin: 2) svstolic blood pressure >I@3 mm Hg; 
3) no new conduction disturbance; b nu significant deteri& 
ration in symptoms. If these criteria were not me! and the 
deviation was minor (e.g., asymptomatic sinus bradycardia), 
the patient continued to receive a regular dose for a futther 
2 weeks. Because. &geographic location, four patients were 
contacted by telephone only, at the end of week 1. None had 
symptomatic deterioration in the 1st week ofany period, and 
all therefore proceeded to a high dose in each period. At the 
end of each treatment period, the patient underwent symp- 
tom assessment, exercise testing, echocardiography and 
blood sampling for drug levels and wore a 24-h Holler 
monitor. 
Exercise testing. The predetermined primary end point of 
the study was change in peak exercise capacity. Symptom- 
limited exercise testing was performed with an elecIronically 
braked bicycle ergometer (Bosch Erg 551). Work load was 
increased by IO W every minute. Tho starting work load 
was varied according to the patient’s ability. This work load 
was determined on the basis of at least two exercise testy 
before study entry and chosen such that each patient could 
exercise for at least 6 and not >I2 min. Reproducibility of 
exercise performance to within IS% before the study was 
enwed by repeated testing. The e1ectrocardiogr.m (ECG) 
was recorded using a Marquette Case-12 system and blood 
pressure by auscultation. Respiratory gas analysis was pcr- 
formed using a Sensormedics MMC Horizon 2 Exercise 
Evaluation Cart. Peak oxygen consumption was identified 
and anaerobic threshold calculated using the method of 
Lipkin et al. (27). 
Symt~toms. Seco.tdary end points of the study were 
change in symptoms and quality of life indexes. Patients 
maintained a dailv score card of the number of episodes of 
chest pain, palpiiation and light-headedncss or bizziness. 
Moving 3.day averages were calculated for each 21.day 
treatment period (28). During their hospital visit at the end of 
each treatment period, patients completed a questionnaire 
consisting of the following: 
1. A Likert Scaleof 24 symptoms scoredon a0 (absent)to 
4 (severe) scale. 
2. The profile of Mood States, which comprises 65 words 
or phrases describing feelings, each of which the pa- 
tient marked on a0 to 4 scale (29). Subsequently, atotal 
score and scores for six aspects of mood were obtained 
(Table 2). 
3. The Health Status Questionnaire: the Sickness Impact 
Profile (30.31). which consists of a series of statements 
describing health.related behavior in I2 categories. Six 
categories, considered IO be most relevant to the study 
group, were used (Table 3). 
4. Period preference: on the final study day. each patient 
was asked to select a preferred treatment period. 
Atnbttlstory Whour electrocardiographic (Haltw) moni- 
taring. Two-channel Halter monitoring was performed 
using “tracker” recorders (Reynold’s Medical). and tapes 
Tabb 3. ERects olNadolol and Vxaoamil on Sickness hmact Prafile h = 161’ 
were analyred on a Pathfinder 3 high-speed analyzer 
(Reynold’s Medical). as previously described (25). Su- 
praventricular and ventricular tachycardia were defined as 
three or more consecutive extnsystoles at a rate of SIXI 
beatslmin. 
Echocardiography and Doppler study. Studies were per- 
formed with a Toshiba Sonolayer SSH GA phased-array 
ultrasound system using B 3.75.MHz transducer for two- 
dimensional echocardiogmphy and a 2.5.MHz transducer for 
Doppler study. Left ventricular end-systolic and end- 
diastolic dimensions, transmitral early (E wave) and late (A 
wave) peak intlow velocities and the left ventricular outflow 
tract velocity were measured as previously described (25). 
Serum drug lawis. Drag levels were measured 6 h after 
the last drug dose and analyred at the Analytical Unit. 
Cardiological Sciences, St. George’s Hospital. London. 
Hi petformance liquid chromatography was used as pre- 
viausly described to determine the serum levels of vern- 
pamil. norverapamil(32) and nadolol (3j). 
Slat&al methods. On the basis of data from previous 
studies (7,9,12). we estimated that between IO and I8 pa- 
tients could detect a difference in exercise capacity among 
the drugs in a crossover design. We decided to analyze the 
results when I6 patients had completed the study. Statistical 
analysis was performed using thecomputer program Minitab 
Data Analysis Sofiware version 7.1 (Minitab Inc.). Data 
were analyzed using a crossover analysis of variance. No 
carryover or period effects were observed, but the symptom 
of palpitation did show a sequence eLct. Associations were 
tested by linear regression analysis, and a correlation co& 
licient was calculated. Results are expressed as mean value 
+ SD. Proportions were compared using a chi-square test. A 
p value 4 0.05 was considered significant. 
ReSUll.5 
Withdrawals amI a&ape elfecls. Patient IO was with- 
drawn from the study at the end of week I, period I, and 
Patient I4 at the end of week I, period 2 (period I had been 
placebo). because of symptom& sinus cdycardia during 
nadolol therapy. No other major adverse effects occurred. 
Four patients (25%) complained of constipation duriy Vera- 
pamil therapy. 
Drue dose and levels. On the basis ofweek I assessment. 
2 of the I6 patients who completed the study received 
nadolol. 80 me (Patieuts 7 and 12): the other I4 received 
I60 mgid. Two-p&ems received verapamil, 240 mg (Patients 
8 and 12); the remainder received 480 mg daily, and two 
patients received “r+ardose” placebo (Patients 7 and 12). 
The verapamil level was I84 ? 82 &teniter (range 57 to 346). 
The norverapamil evel was 260 f 85 @liter (range 133 to 
439). Only one patient (Patient 17) had a verapamil level 
<IW &liter that could be considered subtherapeutic 
(34,351. Nadolol levels were 187 2 76 @liter (range 81 to 
39.Q which are considered within the therapeutic range (36). 
Hemodynamies (Table 4). Rest and exercise heart rates 
were reduced by both drugs, especially nadolol. Exercise 
rate-pressure product was reduced slightly by verapamil but 
markedly by nadolol. Verapamil levels correlated negatively 
with the heart rate at supine rest (r = -0.57; p = O.Od) but 
not with the PR interval or the exercise heart rate. Nadolol 
levels correlated negatively with exercise heart rate (r = 
-0.66; p = 0.005) and less strongly with heart rate at rest 
(r = -0.46; p = 0.07). 
Exercise capacity (Table 5). Exercise duration, maximal 
oxygen consumption and anaerobic threshold were not sig- 
niticantly changed by drug therapy. The 95% confidence 
intervals show that these measures were all reduced by 
nadolol. The peak exercise work load was reduced by 
a10 W in I3 patients (81%) during nadolol therapy and in 4 
patients (25%) during verapamil therapy (p = 0.005, nadolol 
vs. verapamil). Maximal oxygen consumption was increased 
by 810% in only one patient by nadolol (Patient 9) and in 
only two patients by verapamil (Patients 9 and IS) (Fig. I). 
Maximal oxygen consumption was decreased by drug 
Table 6. Effects of Nadolol and Verapamil on Liken Scale of 
Svmptoms (0 = 16) 
‘wrapy in those patients with high values receiving placebo 
(Fig. I). 
Symptoms and Qualify of Life 
Iikert Scale of spptcm (Table 6). The drug &cc, on the 
total symptom score did not achieve statistical significance 
(p = 0.08): therefore, individual symptoms were not ana- 
lyzed. The mean total score for verapamil(9.0) tended to be 
lower than the scores for placebo (10.6) and nadolol (I 1.0); 
the 95% confidence interval for the mean diierence between 
nadolol and verapamil was -0.6 to 4.6. Verapamil tended to 
reduce all cardiac symptoms except palpitation, which was 
reduced by both drugs (Table 6). Nadolol reduced the total 
symptom score by 815% in four patients (25%). Verapamil 
also reduced the total symptom score by alS% in these four 
patients end in an additional five patients (total of nine, 56%). 
Sickness Imtwt Pro& (Tabk 3). The D value for dron 
effect on the total score was of borderline significance at 
0.07. There was a significant drug effect (p = 0.05) on the 
reported performance at work. with the verapamil score 
(216) substantially lower (i.e., better) than the &dolol score 
(8.4) (P = 0.00. The 95% confidence intervals suggest that 
wrap&it was superior to both placebo and mad&l in the 
areas of work, home management and ambulation. Nadolol 
may have had a deleterious effect on the daily activities of 
work and recreation. 
ProAle d Moml Statea (TaMt 2). Drug therapy did not 
have a statistically significant etfect on any aspect of mood. 
Verapamil tended to produce higher scores for the categories 
of tension-anxiety and depression-dejection, hot this was 
offset by better scores in the feeling of fatigue-inertia. The 
mean total score was highest for verapamil, but the confi- 
dence intervals were wide. 
Ibdly symptoms. Symptom diaries were completed by 13 
subjects. Because crossover analysis of variance showed 
that palpitation bad a significant carryover effect @ = 0.04). 
this symptom was excluded from further analysis. Chest 
pain tended to be relieved by nadolol and to ra greater degree 
by verapamil (Fig. 2). The frequency of light-headednew, 
dizziness or presyncope tended to be reduced during the 
verapamil period but increased progressively during nadolol 
treatment (Fig. 3). 
Treatment preference. Thirteen patients (61%) selected 
drug treatment as their preferred period (p = O.!lGl); eight 
chose verrpamil, tivc ndolol. All five patients who chose 
nadolol had been receiving two-blocker therapy ‘before the 
study (two other patients receiving beta.blocker therapy 
before the study chose verapamil and placebo, respectively). 
Of the eight patients who were not receiving drug therapy 
before the study, six preferred vempamil and two placebo. 
Eehoeardtograpby an4 Doppler shnly. Drug therapy did 
not cause any detectable changes in I& ventricular end- 
systolic or end-diastolic diameter, left atrial diameter or in 
the E or A waves (data not shown). An estimated outflow 
tract gradient >30 mm Hg was present in we” patients 
receiving placebo, in five receiviy nadolol nod in four 
receiving verapamil. 
Holler moait&nz. Ambulatory heart rate was reduced 
by both drugs, espe&lly nadolo~(Table 4). The number of 
patients displaying sinus pauses 21.5 s tended to he higher 
with drug therapy (6 receiving placebo, 8 receiving vera 
pamil and II receiving oadolol). but no prolonged pauses 
C-3 s) or episodes of heart block were seen. Total counts of 
ventricular ectopic beats tended to be lower with both drugs 
(Table 4) CD = 0.13). Nonsustained ventricular tacSvcardia 
occurred ii four patients receiving placebo, three receiving 
nadolol and one receiving verapamil. Sopraventriculw 
tachycardia was infrequent (one receiving placebo. one 
receiving verapamil and two receiving ttadolol). 
Discussion 
Exerciv opacity. Both nadolol and verapamil reduced 
heart rate at rest, during daily activity and at peak exercise. 
an effect that was most pronounced for nadolol; however, 
neither drug improved the exercise capacity of the group as 
a whole. In fact. ndolol reduced the peak exercise work 
load in 80% of patients, whereas verapamil had a more 
variable effect. This adverse effect of therapy, especially 
with a beta-blocker. was presumably due to the marked 
reduction in achievable rate-pressure product. It contrasts 
with the beneficial elfat of beta-blockade on exercise in 
coronary artery disease (37.18). An explanation may be that 
patients with hypertrophic cardiomyopathy rely on an in- 
crease in heart rate to iwease cardiac ootpot during exer- 
cise and have little ability to increase stroke volume 09). 
Our findings contrast wirh previous studies on hypwtrc- 
phic cardiomyopathy in which exercise capacity improved 
with verapamil and was unchanged or also improved with 
propmnolol (7.8.12). These diBerences may re0ect the de- 
gree of baseline exercise impairment in different study 
groups (our data suggest hat both drug treatments impaired 
exercise capacity to the greatest extent in patients with the 
Figm 2. Moving 3day avenges for 
the number of episodes of light- 
headedness ordizziness during three 
21.day treatment periods with pla- 
cebo. nadolol and vemyamil in 13 
patients with hypertrophic cardiomy- 
opathy. ‘p value for analysis of vari- 
MEO of drug effect. 
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bes: baseline performance), di5erent drug regimens or the effect of propranolal over nadolol in hypertrophic cardiomy- 
absence of a placebo control in some studies. opaihy cannot be ruled wt. 
Quality of life. The Sickness Impact hofile gives a mea- This study did not adores9 the question of long-term drug 
sore of the effect ofdisease on everyday acrivities. The total therapy. Because treatment periods lasted 3 to 4 weeks, it is 
score of 8% in our study is similar to that reported for likely that the symptomatic and functional responses seen at 
patients atier myocardial infarction (7%) (40) or with chronic this time would be maintained for at least some months. as 
stable angina (12%) (28). Verapamil significantly improved other uncontrolled studies (7.8) suggest. but symptomatic 
the reported performance at work and tentied to produce eflicacy over years is uncertain. This study was not designed 
better scores in ambulation and home management and in to address the question of whether either agent can cause 
the total score relative to those produced by nadolol and regression of hypertmphy (14.41); however. the results 
placebo. Therefore, the study suggests that treatment with make high dose beta-blocker therapy a less attractive agent 
verapamil reduces the impact of disease on the daily lives of to test in regression because of its adverse effect on fimc- 
these patients. tianal capacity. This study also did not attempt to address 
Scores for tension-anxiety and depression-dejection and the effect of these agents on the risk of sudden death. A 
the total score for the Profile of Mood States tended to be number of uncontmlled studies have addressed this question 
higher during verapamil therapy than in the placebo and (26,42), but no controlled trial of therapy in the pmgnosis oi 
nadolol periods. Some of this difference may be due to a hypertrophic cardiomyopathy has yet been performed. 
beneficial eEect of beta-blockade on tension-anxiety, hut we 
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